Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 11/20 | 1.00 |
| ▸ | PIM2 | Q9P1W9 | 11/20 | 1.00 |
| ▸ | CISD1 | Q9NZ45 | 4/20 | 1.00 |
| ▸ | TTR | P02766 | 1/20 | 1.00 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.63 |
| ▸ | MAOA | P21397 | 1/20 | 0.63 |
| ▸ | MAOB | P27338 | 1/20 | 0.63 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.62 |
| ▸ | RXRA | P19793 | 1/20 | 0.61 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.60 |
| ▸ | GSK3B | P49841 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2541388 | 1.00 | PIM1 (1.00) | PIM1PIM2CISD1TTRAKR1B1 | |
| SCHEMBL30753540 | 1.00 | PIM1 (1.00) | PIM1PIM2CISD1TTRAKR1B1 | |
| SCHEMBL2541382 | 1.00 | PIM1 (1.00) | PIM1PIM2CISD1TTRAKR1B1 | |
| SCHEMBL29799457 | 1.00 | PIM1 (1.00) | PIM1PIM2CISD1TTRAKR1B1 | |
| SCHEMBL29825336 | 0.86 | PIM1 (0.76) | PIM1PIM2CISD1TTR | |
| SCHEMBL13749931 | 0.86 | CISD1 (1.00) | PIM1PIM2CISD1TTRGSK3B | |
| SCHEMBL15091290 | 0.86 | PIM1 (0.75) | PIM1PIM2CISD1TTRAKR1B1 | |
| SCHEMBL2544050 | 0.85 | PIM1 (1.00) | PIM1PIM2CISD1TTRAKR1B1 | |
| SCHEMBL2544047 | 0.85 | PIM1 (1.00) | PIM1PIM2CISD1TTRAKR1B1 | |
| SCHEMBL2544398 | 0.85 | PIM1 (1.00) | PIM1PIM2CISD1TTRAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3432886-B1 | PIM KINASE INHIBITORS IN COMBINATION WITH RNA SPLICING MODULATORS/INHIBITORS FOR TREATMENT OF CANCERS | UNIV MARYLAND (US) | 2021-06-02 | — | — | EP | claimed |
| US-20200289606-A1 | PEPTIDE EPOXYKETONE PROTEASOME INHIBITORS IN COMBINATION WITH PIM KINASE INHIBITORS FOR TREATMENT OF CANCERS | ONYX THERAPEUTICS INC (US) | 2020-09-17 | — | — | US | claimed |
| US-20190224270-A1 | PEPTIDE EPOXYKETONE PROTEASOME INHIBITORS IN COMBINATION WITH PIM KINASE INHIBITORS FOR TREATMENT OF CANCERS | ONYX THERAPEUTICS INC (US) | 2019-07-25 | — | — | US | claimed |
| WO-2019070777-A2 | PIM KINASE INHIBITORS IN COMBINATION WITH AUTOPHAGY INHIBITORS FOR TREATMENT OF CANCERS | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) | 2019-04-11 | — | — | WO | claimed |
| EP-3432886-A1 | PIM KINASE INHIBITORS IN COMBINATION WITH RNA SPLICING MODULATORS/INHIBITORS FOR TREATMENT OF CANCERS | University of Maryland, Baltimore County (US) | 2019-01-30 | — | — | EP | claimed |
| WO-2017165495-A1 | PIM KINASE INHIBITORS IN COMBINATION WITH RNA SPLICING MODULATORS/INHIBITORS FOR TREATMENT OF CANCERS | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) | 2017-09-28 | — | — | WO | claimed |
| EP-3021862-B1 | PEPTIDE EPOXYKETONE PROTEASOME INHIBITORS IN COMBINATION WITH PIM KINASE INHIBITORS FOR TREATMENT OF CANCERS | ONYX THERAPEUTICS INC (US) | 2017-08-30 | — | — | EP | claimed |
| US-20160166632-A1 | PEPTIDE EPOXYKETONE PROTEASOME INHIBITORS IN COMBINATION WITH PIM KINASE INHIBITORS FOR TREATMENT OF CANCERS | ONYX THERAPEUTICS INC (US) | 2016-06-16 | — | — | US | claimed |
| EP-3021862-A2 | PEPTIDE EPOXYKETONE PROTEASOME INHIBITORS IN COMBINATION WITH PIM KINASE INHIBITORS FOR TREATMENT OF CANCERS | Onyx Therapeutics, Inc. (US) | 2016-05-25 | — | — | EP | claimed |
| WO-2015009888-A2 | PEPTIDE EPOXYKETONE PROTEASOME INHIBITORS IN COMBINATION WITH PIM KINASE INHIBITORS FOR TREATMENT OF CANCERS | ONYX THERAPEUTICS, INC. (US) | 2015-01-22 | — | — | WO | claimed |
| US-20110263664-A1 | Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2011-10-27 | — | — | US | claimed |
| EP-2217235-A2 | INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER | Musc Foundation for Research Development (US) | 2010-08-18 | — | — | EP | claimed |
| WO-2009064486-A9 | INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER | MUSC FOUND FOR RES DEV (US) | 2009-07-16 | — | — | WO | claimed |
| WO-2009064486-A2 | INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2009-05-22 | — | — | WO | claimed |
| US-12295955-B2 | TTP phosphorylation for the identification of personalized medicines | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2025-05-13 | — | — | US | disclosed |
| US-20240390406-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTIAGING DRUGS | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2024-11-28 | — | — | US | disclosed |
| EP-4467978-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTI-AGING DRUGS | King Faisal Specialist Hospital & Research Centre (SA) | 2024-11-27 | — | — | EP | disclosed |
| EP-2217235-A2 | INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER | Musc Foundation for Research Development (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009064486-A9 | INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER | MUSC FOUND FOR RES DEV (US) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009064486-A2 | INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289606-A1 | PEPTIDE EPOXYKETONE PROTEASOME INHIBITORS IN COMBINATION WITH PIM KINASE INHIBITORS FOR TREATMENT OF CANCERS | PIM1, PIM2, PIM3 | PIM1 1/4885PIM2 2/4885CISD1 2530/4885 |
| US-20110263664-A1 | Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer | PIM1, PIM2, PIM3 | PIM1 1/4885PIM2 2/4885CISD1 3097/4885 |
| US-20160166632-A1 | PEPTIDE EPOXYKETONE PROTEASOME INHIBITORS IN COMBINATION WITH PIM KINASE INHIBITORS FOR TREATMENT OF CANCERS | PIM1, PIM2, PIM3 | PIM1 1/4885PIM2 2/4885CISD1 2530/4885 |
| US-20190224270-A1 | PEPTIDE EPOXYKETONE PROTEASOME INHIBITORS IN COMBINATION WITH PIM KINASE INHIBITORS FOR TREATMENT OF CANCERS | PIM1, PIM2, PIM3 | PIM1 1/4885PIM2 2/4885CISD1 2530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.